Durham-based restor3d secures $104M investment

Restore3d, a Durham maker of three-dimensional printed orthopedic implants, has secured a new investment round valued at $104 million, including $65 million from a global private equity firm and $39 million from existing shareholders.

Swiss-owned Partners Group is taking a minority stake in the company and gaining an undisclosed number of seats on its board of directors, restor3d announced. The company plans to use the proceeds for product innovation, commercial growth and efforts to expand personalized care in orthopedics.

It’s the latest in a line of recent investments in restor3d as investors seek to capitalize on the growing potential for 3D printing in health care. In April, the company picked up $38 million in venture funding from existing investors and new ones, including Summers Value Partners of Denver. In 2024, restor3d secured $70 million in Series A funding, made up of $55 million from private investors and $15 million in debt financing.

“With Partners Group’s support, we will continue to deliver innovations that empower surgeons and improve outcomes for patients across the full spectrum of joint replacement,” restor3d CEO Kurt Jacobus said in a news release.

Added Ashley Torres, a management member in private equity at Partners Group: “restor3d is solving a key issue in the orthopedic market, namely that procedures have often relied on off-the-shelf products that cannot accommodate different patient anatomies. restor3d addresses this challenge by delivering rapid, precise patient-specific implants that lead to better surgical fit and function, ultimately improving patient outcomes.”

Founded in 2017 as a spinout from Duke University, restor3d produces musculoskeletal implants developed through its design software, vertically integrated manufacturing processes and input from orthopedic surgeons and hospitals.

Its products include a total knee replacement system and an ankle replacement system, both using 3D printing techniques to help customize for specific types of patients. Both have received clearance from the U.S. Food and Drug Administration under the 510(k) premarket regulatory process. Two additional devices – for shoulder and hip replacement – have been submitted to the FDA for 510(k) clearance.

Restor3d expanded its operations in Research Triangle Park in late 2023, opening a 50,000-square-foot location for both office space and manufacturing.

Partners Group, with $174 billion in assets under management, has its U.S. headquarters in Broomfield, Colo.